Full archive
Pharmacogenomics
Week of 20 May 2026
4 articles
Geno'X Veille — genox-veille.fr
Key takeaways this week
- ►ACKR1 — Duffy-null genotyping before clozapine: UK guideline to prevent unjustified exclusion of African-ancestry patients from the best therapy for refractory schizophrenia.
- ►CYP2C19 neurointerventions — 54.9% reduction in intracranial ischemic events post-stenting by genotype-guided antiplatelet therapy: extending the benefit beyond cardiology.
- ►CYP2C19 phenoconversion — CYP2C19 inhibitors (not CYP3A4) induce clinically significant phenoconversion in normal metabolizers on post-PCI clopidogrel.
- ►SLCO1B1 — coproporphyrin I as an endogenous biomarker for OATP1B1 phenoconversion in clinical routine: proof of concept in a polymedicated cohort.
Category:
Filters··Min. score
4 articles of 4
Sort
ACKR1
PubMed★ Top pick
ACKR1/Duffy-null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).
ACKR1/Duffy-null associated neutropenia (ADAN) in clozapine-treated patients
9
/10
New recommendationAdverse reaction
British Journal of Clinical Pharmacology 2026· MayRead
CYP2C19
PubMedImpact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention.
CYP2C19 phenoconversion under drug inhibitors after percutaneous coronary intervention
8
/10
CardiologyPhenoconversionAdverse reaction
Clinical Pharmacology and Therapeutics 2026· MayRead
CYP2C19
PubMedCYP2C19 genotype-guided antiplatelet therapy to prevent thromboembolic events after stent-assisted coil embolization of unruptured intracranial aneurysms: a retrospective cohort study.
Unruptured intracranial aneurysm treated by stent-assisted coil embolization
7
/10
CardiologyDose recommendationAdverse reaction
Journal of Neurointerventional Surgery 2026· MayRead
SLCO1B1
PubMedBiomarker-Based Prediction of OATP1B1 Activity in Clinical Routine — Investigating Coproporphyrins as Markers for Drug-Drug-Gene Interactions.
SLCO1B1 phenoconversion in clinical routine: detection by endogenous biomarker
7
/10
DiabetesPhenoconversionNew interaction
Clinical Pharmacology and Therapeutics 2026· MayRead
References and sources
- ACKR1 — ACKR1/Duffy-null associated neutropenia (ADAN) in clozapine-treated patients. British Journal of Clinical Pharmacology 2026. PMID 42125771. Score 9/10. https://pubmed.ncbi.nlm.nih.gov/42125771/
- CYP2C19 — Unruptured intracranial aneurysm treated by stent-assisted coil embolization. Journal of Neurointerventional Surgery 2026. PMID 40850765. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/40850765/
- CYP2C19 — CYP2C19 phenoconversion under drug inhibitors after percutaneous coronary intervention. Clinical Pharmacology and Therapeutics 2026. PMID 42138382. Score 8/10. https://pubmed.ncbi.nlm.nih.gov/42138382/
- SLCO1B1 — SLCO1B1 phenoconversion in clinical routine: detection by endogenous biomarker. Clinical Pharmacology and Therapeutics 2026. PMID 42145189. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/42145189/